- Home
- RARE vs TDS Comparison
RARE vs TDS Comparison
Compare RARE & TDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- TDS
- Stock Information
- Founded
- RARE 2010
- TDS 1968
- Country
- RARE United States
- TDS United States
- Employees
- RARE N/A
- TDS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- TDS Telecommunications Equipment
- Sector
- RARE Health Care
- TDS Telecommunications
- Exchange
- RARE Nasdaq
- TDS Nasdaq
- Market Cap
- RARE 3.5B
- TDS 3.9B
- IPO Year
- RARE 2014
- TDS N/A
- Fundamental
- Price
- RARE $36.68
- TDS $35.17
- Analyst Decision
- RARE Strong Buy
- TDS Buy
- Analyst Count
- RARE 15
- TDS 2
- Target Price
- RARE $90.53
- TDS $50.00
- AVG Volume (30 Days)
- RARE 1.1M
- TDS 806.3K
- Earning Date
- RARE 07-31-2025
- TDS 08-01-2025
- Dividend Yield
- RARE N/A
- TDS 0.47%
- EPS Growth
- RARE N/A
- TDS N/A
- EPS
- RARE N/A
- TDS N/A
- Revenue
- RARE $590,689,000.00
- TDS $4,856,000,000.00
- Revenue This Year
- RARE $18.94
- TDS N/A
- Revenue Next Year
- RARE $28.93
- TDS $0.40
- P/E Ratio
- RARE N/A
- TDS N/A
- Revenue Growth
- RARE 33.46
- TDS N/A
- 52 Week Low
- RARE $29.59
- TDS $17.90
- 52 Week High
- RARE $60.37
- TDS $41.21
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- TDS 52.91
- Support Level
- RARE $36.03
- TDS $34.12
- Resistance Level
- RARE $37.74
- TDS $36.00
- Average True Range (ATR)
- RARE 1.46
- TDS 0.96
- MACD
- RARE -0.01
- TDS 0.13
- Stochastic Oscillator
- RARE 26.56
- TDS 70.29
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.